Harbin Pharmaceutical Group Co., Ltd. (SHA:600664)
China
· Delayed Price · Currency is CNY 3.690
+0.010 (0.27%)
Apr 28, 2025, 2:45 PM CST
SHA:600664 Revenue
Harbin Pharmaceutical Group had revenue of 4.17B CNY in the quarter ending March 31, 2025, with 0.78% growth. This brings the company's revenue in the last twelve months to 16.21B, up 3.45% year-over-year. In the year 2024, Harbin Pharmaceutical Group had annual revenue of 16.18B with 4.65% growth.
Revenue (ttm)
16.21B
Revenue Growth
+3.45%
P/S Ratio
0.57
Revenue / Employee
1.64M
Employees
9,853
Market Cap
9.27B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16.18B | 719.28M | 4.65% |
| Dec 31, 2023 | 15.46B | 1.65B | 11.93% |
| Dec 31, 2022 | 13.81B | 1.01B | 7.86% |
| Dec 31, 2021 | 12.80B | 2.01B | 18.66% |
| Dec 31, 2020 | 10.79B | -1.04B | -8.76% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jiangsu Hengrui Medicine | 29.19B |
| Shenzhen Mindray Bio-Medical Electronics | 37.11B |
| WuXi AppTec | 37.92B |
| Zhangzhou Pientzehuang Pharmaceutical., | 10.79B |
| Aier Eye Hospital Group | 21.81B |
| Sichuan Biokin Pharmaceutical | 5.82B |
| Shanghai United Imaging Healthcare | 10.30B |
| Yunnan Baiyao Group Co.,Ltd | 40.03B |